HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo’s New Papa: CEO Brings Product Development Know-How To Post

This article was originally published in The Tan Sheet

Executive Summary

Joseph Papa brings 30 years of experience in healthcare and specialty generic pharmaceutical industries to his new position as president and CEO of Perrigo, the private-label manufacturer announced Sept. 11

You may also be interested in...

Perrigo Builds Sales On Smoking Cessation, Eyes Prilosec OTC In 2007

Pursuit of private-label omeprazole for a possible 2007 launch fits Perrigo's ongoing strategy of focusing on new products to drive sales growth

New Products In Brief

Perrigo generic Nicorette approval: The Allegan, Mich.-based generics manufacturer has received FDA approval to market store-brand versions of GlaxoSmithKline's Nicorette Fresh Mint (coated nicotine polacrilex gum 2 mg and 4 mg) smoking cessation gum, the firm announces June 14. Retail sales for GSK's Fresh Mint gum were approximately $100 mil. for the past 12 months. Perrigo currently produces generic versions of GSK's uncoated NRT gum products as well as nicotine polacrilex lozenges equivalent to GSK's Commit product. "We are pleased with this important addition to our store brand nicotine replacement therapy product offerings, even though some sales may come at the expense of our uncoated gum products," Executive VP and General Manager - Perrigo Consumer Healthcare John Hendrickson states. The product will begin shipping to food, drug, mass market, dollar store and club store retailers in the fourth quarter and will cost approximately 25% to 40% less than the branded, the firm says...

Replacing Pseudoephedrine Easier Said Than Done, OTC Firms Find

Reformulating pseudoephedrine products has posed a greater challenge than expected for a number of firms, as passage of a federal bill restricting sale of the ingredient looms





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts